These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 37391283

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y, Zeng N, Zhang F, Huang Y, Tian Y.
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
    Akpinar C, Oz DK, Oktar A, Suer E, Ozden E, Haliloglu N, Gulpinar O, Gokce MI, Gogus C, Baltaci S.
    Clin Genitourin Cancer; 2024 Jun; 22(3):102071. PubMed ID: 38555682
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X, Xu J, Zhong S, Zou J, Cheng Z, Ding Z, Zhou X.
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [Abstract] [Full Text] [Related]

  • 7. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
    Wang YM, Shang JW, Dong L, Liang LH, Zhao RZ, Liang C, Wang SQ, Xia W, Cheng G, Hua LX.
    Zhonghua Zhong Liu Za Zhi; 2023 Nov 23; 45(11):942-947. PubMed ID: 37968079
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI.
    Liang L, Qi F, Cheng Y, Zhang L, Cao D, Cheng G, Hua L.
    Sci Rep; 2021 Mar 15; 11(1):6048. PubMed ID: 33723287
    [Abstract] [Full Text] [Related]

  • 10. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
    Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Fossati N, Martini A, Cucchiara V, Picker W, Haug E, Ratnani P, Haines K, Lewis S, Sujit N, Selvaggio O, Sanguedolce F, Macarini L, Cormio L, Nordström T, Tewari A, Briganti A, Boström PJ, Carrieri G.
    Eur Urol Oncol; 2021 Dec 15; 4(6):971-979. PubMed ID: 32972896
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana-Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais-Bahrami S.
    Cancer; 2022 Sep 15; 128(18):3287-3296. PubMed ID: 35819253
    [Abstract] [Full Text] [Related]

  • 14. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A, Dell'Oglio P, De Cobelli F, Esposito A, Gandaglia G, Fossati N, Brembilla G, Cristel G, Cardone G, Deho' F, Losa A, Suardi N, Gaboardi F, Del Maschio A, Montorsi F, Briganti A.
    Eur Urol Oncol; 2018 May 15; 1(1):29-36. PubMed ID: 31100225
    [Abstract] [Full Text] [Related]

  • 15. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
    Wang S, Kozarek J, Russell R, Drescher M, Khan A, Kundra V, Barry KH, Naslund M, Siddiqui MM.
    Eur Urol Oncol; 2024 Apr 15; 7(2):189-203. PubMed ID: 37640584
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.